Market Access/ News/ News/ News/ Patients FDA sets June date for latest review of Merck’s last-ditch antibiotic Phil Taylor antibiotic, Merck & Co, Recarbrio, respiratory 0 Comment The FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new Share X FDA sets June date for latest review of Merck’s last-ditch antibiotic https://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/
Market Access/ News/ News Merck’s last-resort antibiotic Recarbrio nears EU approval Phil Taylor antibiotic, CHMP, ema, Merck & Co, multidrug resistance, Recarbrio 0 Comment Merck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share X Merck’s last-resort antibiotic Recarbrio nears EU approval https://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
